Prognostic Stratification of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy and Quality Surgery in LA-ESCC.
Some advanced esophageal cancer patients benefit significantly from additional immunotherapy after surgery, helping doctors decide who needs it most.
This multicenter observational cohort study examined prognostic stratification of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy and quality surgery in la-escc. The abstract reports that among LA-ESCC patients receiving NCIT and high-quality surgery, adjuvant immunotherapy significantly improves 3-year DFS in the non-MPR/ypN+ subgroup, with no significant benefit in other subgroups.
What the study was
- Study design
- Multicenter observational cohort study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Journal of thoracic and cardiovascular surgery
Why it surfaced
Multicenter observational cohort study relevant to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; score assigned conservatively from the PubMed abstract and metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.